L3VLUP
ProSign in

JNJ · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

JNJVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • JNJ
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterJNJVRTX
Q3 202030 holders, $26.2bn31 holders, $21.9bn
Q4 202032 holders, $26.6bn30 holders, $18.4bn
Q1 202131 holders, $25.3bn31 holders, $15.4bn
Q2 202137 holders, $25.6bn30 holders, $12.7bn
Q3 202140 holders, $24.1bn35 holders, $10.1bn
Q4 202133 holders, $25.2bn28 holders, $12.4bn
Q1 202235 holders, $28.2bn23 holders, $16.1bn
Q2 202233 holders, $26.9bn25 holders, $18.1bn
Q3 202236 holders, $25.4bn22 holders, $18.4bn
Q4 202235 holders, $27.6bn28 holders, $18.4bn
Q1 202342 holders, $24.5bn26 holders, $21.4bn
Q2 202338 holders, $25.0bn27 holders, $24.7bn
Q3 202337 holders, $18.9bn33 holders, $24.3bn
Q4 202331 holders, $19.0bn32 holders, $28.6bn
Q1 202432 holders, $19.7bn31 holders, $29.8bn
Q2 202435 holders, $20.4bn29 holders, $33.4bn
Q3 202428 holders, $22.3bn27 holders, $33.5bn
Q4 202437 holders, $20.4bn26 holders, $28.5bn
Q1 202532 holders, $20.5bn21 holders, $35.4bn
Q2 202531 holders, $18.4bn21 holders, $32.3bn
Q3 202532 holders, $23.7bn22 holders, $25.9bn
Q4 202529 holders, $27.8bn26 holders, $31.8bn
Q1 202634 holders, $35.6bn25 holders, $31.8bn
Q2 202633 holders, $39.1bn26 holders, $34.6bn
JNJ

Johnson & Johnson

Holders
34
Reported value
$35.6bn
Buyers
21
Sellers
18

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only JNJ (15)

AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Citadel Advisors LLC, Dodge & Cox, Farallon Capital Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Markel Group Inc, Millennium Management LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Verition Fund Management LLC, Winton Group Ltd

Only VRTX (6)

Baillie Gifford & Co, Caxton Associates LLP, ExodusPoint Capital Management LP, Holocene Advisors LP, Renaissance Technologies LLC, Two Sigma Investments LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →